| scholarly article | Q13442814 |
| P50 | author | Robin Murray | Q7352679 |
| Paul M. Grasby | Q21094787 | ||
| Philip McGuire | Q37834611 | ||
| Oliver Howes | Q42551337 | ||
| Lucia Valmaggia | Q42823642 | ||
| Elvira Bramon | Q52013079 | ||
| Matthew R Broome | Q60622769 | ||
| Andrew Montgomery | Q86910724 | ||
| Marie-Claude Asselin | Q91750627 | ||
| Paul Tabraham | Q114386302 | ||
| Isabel Valli | Q114386357 | ||
| P2093 | author name string | Louise Johns | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| schizophrenia | Q41112 | ||
| striatum | Q1319792 | ||
| P304 | page(s) | 13-20 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Elevated striatal dopamine function linked to prodromal signs of schizophrenia | |
| P478 | volume | 66 |
| Q47605592 | 30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis |
| Q50096180 | A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia |
| Q37736987 | A neural model of the loss of self in schizophrenia |
| Q34660862 | A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia |
| Q34103482 | A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. |
| Q47664140 | A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia |
| Q99604509 | A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach |
| Q26748778 | A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis |
| Q37678875 | A synthesis of evidence on inhibitory control and auditory hallucinations based on the Research Domain Criteria (RDoC) framework |
| Q38194451 | A systems neuroscience perspective of schizophrenia and bipolar disorder |
| Q40730801 | Aberrant Salience Is Related to Reduced Reinforcement Learning Signals and Elevated Dopamine Synthesis Capacity in Healthy Adults. |
| Q89475585 | Aberrant Temporal Connectivity in Persons at Clinical High Risk for Psychosis |
| Q35044556 | Aberrant salience, self-concept clarity, and interview-rated psychotic-like experiences. |
| Q35116201 | Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis |
| Q48394255 | Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis |
| Q30450082 | Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis |
| Q55345386 | Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis. |
| Q38060250 | Abnormal striatal dopamine transmission in schizophrenia |
| Q51740117 | Accumbens dopamine D2 receptors increase motivation by decreasing inhibitory transmission to the ventral pallidum. |
| Q38846609 | Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model |
| Q37381202 | Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency |
| Q34283319 | Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. |
| Q37489007 | Adversity in childhood linked to elevated striatal dopamine function in adulthood |
| Q36579986 | Altered G Protein Coupling in Olfactory Neuroepithelial Cells From Patients With Schizophrenia |
| Q45839278 | Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis |
| Q37019129 | Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia |
| Q33762485 | Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis |
| Q33839379 | An Integrative Perspective on the Role of Dopamine in Schizophrenia |
| Q26991569 | An Overview of the Association between Schizotypy and Dopamine |
| Q92898104 | An Update on Promising Biomarkers in Schizophrenia |
| Q33933997 | An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia |
| Q50309747 | An in Silico, Biomarker-Based Method for the Evaluation of Virtual Neuropsychiatric Drug Effects |
| Q91236277 | An integrative framework for perceptual disturbances in psychosis |
| Q36946136 | Are persistent delusions in schizophrenia associated with aberrant salience? |
| Q22251180 | Asignación de relevancia (salience) y desregulación del sistema dopaminérgico |
| Q28069770 | Attachment, Neurobiology, and Mentalizing along the Psychosis Continuum |
| Q50081191 | Attention Deficit Hyperactivity Disorder Symptoms and Psychosis in 22q11.2 Deletion Syndrome |
| Q38114968 | Attenuated psychosis syndrome in DSM-5. |
| Q41878026 | Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease |
| Q30450235 | Basic disturbances of information processing in psychosis prediction |
| Q38150484 | Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function |
| Q30596256 | Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics |
| Q33752862 | Brain imaging and transition to psychosis |
| Q50350029 | Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders |
| Q57576217 | Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study |
| Q38621565 | Can neuroimaging be used to predict the onset of psychosis? |
| Q39179530 | Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. |
| Q34556900 | Cerebellar Morphology and Procedural Learning Impairment in Neuroleptic-Naive Youth at Ultrahigh Risk of Psychosis |
| Q30584569 | Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity |
| Q37711124 | Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment |
| Q34699360 | Cognition, dopamine and bioactive lipids in schizophrenia |
| Q36314731 | Cognition-emotion dysinteraction in schizophrenia |
| Q55305236 | Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies. |
| Q50531241 | Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients. |
| Q31108616 | Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics |
| Q50420782 | Core beliefs in healthy youth and youth at ultra high-risk for psychosis: Dimensionality and links to depression, anxiety, and attenuated psychotic symptoms |
| Q30372428 | Corticolimbic dysfunction during facial and prosodic emotional recognition in first-episode psychosis patients and individuals at ultra-high risk. |
| Q47749243 | Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study |
| Q50420904 | Current perspectives on incentive salience and applications to clinical disorders. |
| Q38820530 | DNA Damage in Major Psychiatric Diseases |
| Q33715071 | Decreased Expression of α-Synuclein, Nogo-A and UCH-L1 in Patients with Schizophrenia: A Preliminary Serum Study |
| Q50192659 | Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis |
| Q41068640 | Depression predicts persistence of paranoia in clinical high-risk patients to psychosis: results of the EPOS project |
| Q36113538 | Dermatoglyphic asymmetries and fronto-striatal dysfunction in young adults reporting non-clinical psychosis |
| Q52573337 | Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. |
| Q27009237 | Developmental mechanisms in the prodrome to psychosis |
| Q35772615 | Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia |
| Q43807805 | Does human presynaptic striatal dopamine function predict social conformity? |
| Q36636329 | Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task |
| Q92549251 | Dopamine and glutamate in schizophrenia: biology, symptoms and treatment |
| Q99418608 | Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis |
| Q34068906 | Dopamine function in cigarette smokers: an [¹⁸F]-DOPA PET study |
| Q58183040 | Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia – relationship with COMT Val108/158 Met polymorphism, gender and symptomatology |
| Q36928703 | Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study |
| Q47550545 | Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. |
| Q36939999 | Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations |
| Q92833459 | Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model |
| Q33620153 | Dysfunction and Dysconnection in Cortical-Striatal Networks during Sustained Attention: Genetic Risk for Schizophrenia or Bipolar Disorder and its Impact on Brain Network Function |
| Q36690658 | Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia. |
| Q37331631 | Early detection and intervention in bipolar affective disorder: targeting the development of the disorder |
| Q26823735 | Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update |
| Q37438631 | Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia |
| Q35950807 | Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study |
| Q36579965 | Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction |
| Q39037300 | Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. |
| Q64267299 | Emerging Temporal Lobe Dysfunction in People at Clinical High Risk for Psychosis |
| Q36244988 | Emotion recognition in individuals at clinical high-risk for schizophrenia. |
| Q64104363 | Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia |
| Q37975281 | Ethical implications for clinical practice and future research in "at risk" individuals. |
| Q37945156 | Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. |
| Q36070250 | Examining associations between psychosis risk, social anhedonia, and performance of striatum-related behavioral tasks |
| Q37480047 | Executive function, neural circuitry, and genetic mechanisms in schizophrenia |
| Q38897362 | Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition |
| Q38759965 | Explaining Delusions: Reducing Uncertainty Through Basic and Computational Neuroscience |
| Q39818506 | From maps to mechanisms through neuroimaging of schizophrenia |
| Q36872150 | From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments |
| Q93262850 | Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [18F]DOPA PET and fMRI study |
| Q47388815 | Functional dysconnectivity of the limbic loop of frontostriatal circuits in first-episode, treatment-naive schizophrenia |
| Q27320072 | Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation |
| Q33533750 | Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance |
| Q36992322 | Glutamate and dopamine in schizophrenia: an update for the 21st century |
| Q37215695 | Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study |
| Q90748306 | Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study |
| Q30580970 | Gray matter volumetric abnormalities associated with the onset of psychosis |
| Q37349833 | HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis. |
| Q37518159 | Handwriting analysis indicates spontaneous dyskinesias in neuroleptic naïve adolescents at high risk for psychosis |
| Q28275290 | Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia |
| Q35158156 | Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis |
| Q28087255 | How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis |
| Q37829639 | How have developments in molecular imaging techniques furthered schizophrenia research? |
| Q35551673 | Identification and treatment of a pineal region tumor in an adolescent with prodromal psychotic symptoms |
| Q101403283 | Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study |
| Q37666517 | Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain |
| Q55186763 | Inconclusive Evidence in Support of the Dopamine Hypothesis of Psychosis: Why Neurobiological Research Must Consider Medication Use, Adjust for Important Confounders, Choose Stringent Comparators, and Use Larger Samples. |
| Q47222599 | Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort. |
| Q47357393 | Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis |
| Q35048055 | Increased intra-individual variability of cognitive processing in subjects at risk mental state and schizophrenia patients |
| Q36621056 | Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia |
| Q59784320 | Increased resting perfusion of the hippocampus in high positive schizotypy: A pseudocontinuous arterial spin labeling study |
| Q38976397 | Insights About Striatal Circuit Function and Schizophrenia From a Mouse Model of Dopamine D2 Receptor Upregulation |
| Q40819661 | Insular Dysfunction Reflects Altered Between-Network Connectivity and Severity of Negative Symptoms in Schizophrenia during Psychotic Remission |
| Q35950814 | Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis |
| Q38640149 | Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review |
| Q36940031 | Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition |
| Q34703195 | Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials |
| Q37979672 | Is clinical intervention in the ultra high risk phase effective? |
| Q42862248 | Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia? |
| Q47584894 | Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study |
| Q37800531 | Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia |
| Q38076170 | Long-acting injectable antipsychotics in early psychosis: a literature review |
| Q37563725 | Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. |
| Q34639853 | Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth |
| Q36669230 | Low maternal hemoglobin during pregnancy and diminished neuromotor and neurocognitive performance in offspring with schizophrenia |
| Q28077939 | Making Sense of: Sensitization in Schizophrenia |
| Q33936729 | Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal period |
| Q36941951 | Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. |
| Q30371206 | Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype. |
| Q37256211 | Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study |
| Q37714965 | Modeling excess striatal D2 receptors in mice |
| Q34165986 | Modeling motivational deficits in mouse models of schizophrenia: behavior analysis as a guide for neuroscience |
| Q91931406 | Models of persecutory delusions: a mechanistic insight into the early stages of psychosis |
| Q37262953 | Molecular imaging as a guide for the treatment of central nervous system disorders |
| Q30383611 | Molecular substrates of schizophrenia: homeostatic signaling to connectivity |
| Q47836636 | Motion energy analysis reveals altered body movement in youth at risk for psychosis |
| Q57494356 | Motor clusters reveal differences in risk for psychosis, cognitive functioning, and thalamocortical connectivity: evidence for vulnerability subtypes |
| Q39990502 | Movement abnormalities and psychotic-like experiences in childhood: markers of developing schizophrenia? |
| Q83680710 | Movement disorders are associated with schizotypy in unaffected siblings of patients with non-affective psychosis |
| Q90750994 | Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome |
| Q47985145 | Neural Responses to Smoking Cues in Schizophrenia. |
| Q37228333 | Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis |
| Q36408037 | Neural signals encoding shifts in beliefs |
| Q91637851 | Neuroactive Steroids and Cognitive Functions in First-Episode Psychosis Patients and Their Healthy Siblings |
| Q35167455 | Neurochemical characterization of the tree shrew dorsal striatum |
| Q34552937 | Neuroimaging findings in the at-risk mental state: a review of recent literature |
| Q34322929 | Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. |
| Q57144224 | Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients |
| Q37009643 | Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. |
| Q30582343 | Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research |
| Q47404190 | Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia |
| Q47596297 | Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia |
| Q38409835 | No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol |
| Q41918764 | Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse |
| Q95270886 | Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia |
| Q38119411 | Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the potential of protein-based formulations using glycomacropeptide |
| Q38191255 | Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function |
| Q33671729 | Orbitofrontal dopamine depletion upregulates caudate dopamine and alters behavior via changes in reinforcement sensitivity |
| Q36914587 | Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method |
| Q34527656 | Pathway-Specific Dopamine Abnormalities in Schizophrenia |
| Q38156171 | Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis |
| Q35550864 | Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia |
| Q34569376 | Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study |
| Q37479158 | Physical activity level and medial temporal health in youth at ultra high-risk for psychosis |
| Q38214798 | Polyunsaturated fatty acids in emerging psychosis: a safer alternative? |
| Q37975237 | Positron emission tomography in psychiatric disorders |
| Q50659891 | Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. |
| Q50025633 | Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis |
| Q30471857 | Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis. |
| Q64053015 | Preliminary evidence of increased striatal dopamine in a nonhuman primate model of maternal immune activation |
| Q37412403 | Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia |
| Q36242277 | Prescription stimulant use is associated with earlier onset of psychosis. |
| Q48219402 | Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study |
| Q38848472 | Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions |
| Q37825635 | Presynaptic dopamine in schizophrenia. |
| Q38219577 | Presynaptic dopaminergic function: implications for understanding treatment response in psychosis |
| Q34415890 | Presynaptic regulation of dopamine transmission in schizophrenia |
| Q57106875 | Probabilistic Category Learning and Striatal Functional Activation in Psychosis Risk |
| Q36871782 | Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. |
| Q47553108 | Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. |
| Q50353546 | Psychotic reactions to daily life stress and dopamine function in people with severe hearing impairment |
| Q45979559 | Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia. |
| Q33662861 | Reasons for cannabis use among youths at ultra high risk for psychosis. |
| Q35910290 | Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders |
| Q38254737 | Recent advances in parametric neuroreceptor mapping with dynamic PET: basic concepts and graphical analyses |
| Q35536864 | Reduced activation in the ventral striatum during probabilistic decision-making in patients in an at-risk mental state |
| Q37699352 | Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study |
| Q36850586 | Reduced presynaptic dopamine activity in adolescent dorsal striatum |
| Q33707670 | Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans. |
| Q41046867 | Reinforcement Learning Performance and Risk for Psychosis in Youth |
| Q38745478 | Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia. |
| Q30475598 | Research in people with psychosis risk syndrome: a review of the current evidence and future directions |
| Q35624912 | Resting cortisol level, self-concept, and putative familial environment in adolescents at ultra high-risk for psychotic disorders |
| Q30474245 | Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system |
| Q37437144 | Salience attribution and its relationship to cannabis-induced psychotic symptoms. |
| Q56959104 | Schizophrenia |
| Q64085157 | Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms |
| Q34023115 | Schizophrenia: an integrated sociodevelopmental-cognitive model |
| Q35844335 | Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. |
| Q34579973 | Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis |
| Q47752891 | Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis |
| Q38720132 | Sensing the Worst: Neurophenomenological Perspectives on Neutral Stimuli Misperception in Schizophrenia Spectrum |
| Q41656821 | Sex differences in morning cortisol in youth at ultra-high-risk for psychosis. |
| Q41975639 | Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action |
| Q34023184 | Spatial working memory ability in individuals at ultra high risk for psychosis |
| Q36311806 | Spontaneous parkinsonisms and striatal impairment in neuroleptic free youth at ultrahigh risk for psychosis |
| Q48387730 | Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome |
| Q26830600 | Stress and neurodevelopmental processes in the emergence of psychosis |
| Q27316877 | Striatal Activity is Associated with Deficits of Cognitive Control and Aberrant Salience for Patients with Schizophrenia |
| Q35950793 | Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome |
| Q37375004 | Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis |
| Q57403286 | Striatal dopamine synthesis capacity in twins discordant for schizophrenia |
| Q36621010 | Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis |
| Q38805970 | Striatal dopamine, reward, and decision making in schizophrenia |
| Q33635522 | Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study |
| Q34250017 | Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies |
| Q34127239 | Striatal volumes and dyskinetic movements in youth at high-risk for psychosis |
| Q91610778 | Striatum-related functional activation during reward- versus punishment-based learning in psychosis risk |
| Q89748024 | Structural and functional imaging markers for susceptibility to psychosis |
| Q97519770 | Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models |
| Q30390106 | Symptom dimensions are associated with reward processing in unmedicated persons at risk for psychosis |
| Q38032249 | Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis |
| Q33604654 | Targeting metabotropic glutamate receptors for novel treatments of schizophrenia |
| Q41471091 | Teamwork matters: coordinated neuronal activity in brain systems relevant to psychiatric disorders |
| Q34279073 | The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions |
| Q35382798 | The 4th Schizophrenia International Research Society Conference, 5-9 April 2014, Florence, Italy: a summary of topics and trends |
| Q49551829 | The Circuitry of Dopamine System Regulation and its Disruption in Schizophrenia: Insights Into Treatment and Prevention. |
| Q91972968 | The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia |
| Q57715244 | The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study |
| Q38976291 | The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia |
| Q42635344 | The contribution of neuroimaging to understanding schizophrenia; past, present, and future |
| Q27026331 | The development, past achievements, and future directions of brain PET |
| Q22242827 | The dopamine hypothesis of schizophrenia: version III--the final common pathway |
| Q47105586 | The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life |
| Q57463081 | The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study |
| Q46296210 | The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders |
| Q83227219 | The effects of psychosocial stress on dopaminergic function and the acute stress response |
| Q48131311 | The emerging biology of delusions. |
| Q37633236 | The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. |
| Q37062793 | The nature of dopamine dysfunction in schizophrenia and what this means for treatment |
| Q38232366 | The neurobiology and treatment of first-episode schizophrenia |
| Q42907698 | The neuromodulator of exploration: A unifying theory of the role of dopamine in personality |
| Q38061036 | The psychosis high-risk state: a comprehensive state-of-the-art review |
| Q91042528 | The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients |
| Q43922950 | The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole |
| Q47832927 | The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis |
| Q58793943 | The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study |
| Q91130303 | The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study |
| Q37064137 | The role of aberrant salience and self-concept clarity in psychotic-like experiences. |
| Q27026637 | The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia |
| Q33897463 | The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function |
| Q87897513 | The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia |
| Q37766014 | Toward a neurobiology of delusions |
| Q38434642 | Transcriptional signatures of connectomic subregions of the human striatum. |
| Q30447851 | Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals |
| Q26860217 | Translating the MAM model of psychosis to humans |
| Q38218090 | Translational studies of goal-directed action as a framework for classifying deficits across psychiatric disorders |
| Q37635300 | Treadmill exercise enhances NMDA receptor expression in schizophrenia mice |
| Q49032517 | Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia |
| Q36584724 | Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters |
| Q43092490 | Understanding pathophysiology is crucial in linking clinical staging to targeted therapeutics |
| Q37609217 | Unexpected global impact of VTA dopamine neuron activation as measured by opto-fMRI. |
| Q30500752 | Using computational patients to evaluate illness mechanisms in schizophrenia |
| Q36332602 | Using human brain imaging studies as a guide toward animal models of schizophrenia. |
| Q50128836 | Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis |
| Q26829555 | Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis |
| Q47269977 | What Can Different Motor Circuits Tell Us About Psychosis? An RDoC Perspective |
| Q38249908 | What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. |
| Q46082587 | White-matter markers for psychosis in a prospective ultra-high-risk cohort |
| Q41850151 | Who is at risk for a psychotic disorder? |
| Q52562792 | α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. |
Search more.